Clinical trials · Philadelphia, PA
Hematologic Malignancy clinical trials in Philadelphia
We’re tracking 16 recruiting hematologic malignancy studies with a site in or near Philadelphia — including Phase 1, Phase 1/Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT06579469Recruiting
Study of later effects of CAR T cell therapy
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
Philadelphia, PennsylvaniaAges Up to 30 years - NCT03680677Recruiting
Checking frailty to guide treatment in older blood cancer patients
This study checks “frailty” (how strong and able you are to function) to help choose better treatment for people age 60+ with certain blood cancers like acute leukemia or MDS. It may help clinicians tailor care before major treatments like transplant or CAR T-cell therapy.
Philadelphia, PennsylvaniaAges 60 years+ - NCT06967467Enrolling by invitation
Testing Penicillin Allergies in Blood Cancer Patients
This study tests if an antibiotic allergy evaluation can help improve treatment for people with blood cancers. It aims to safely remove inaccurate penicillin allergy labels, potentially allowing use of better antibiotics.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07133074RecruitingPhase 4
Testing penicillin allergy labels in blood cancer patients
This trial checks whether people with blood cancers who think they are allergic to penicillin or related antibiotics can safely take these medicines again. It aims to remove incorrect allergy labels to improve treatment options.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Philadelphia, PennsylvaniaAges 1–21 - NCT07121140Recruiting
Home blood transfusions for cancer patients
This trial tests whether it is safe to give blood transfusions at home instead of in the hospital. It is for people who need regular blood transfusions for their cancer care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Philadelphia, PennsylvaniaAges 6 months–25 years - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Philadelphia, PennsylvaniaAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Philadelphia, PennsylvaniaAges Any age - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05041309Enrolling by invitation
Long-term follow-up after a Kite gene-cell infusion
This study checks on people long after they received a gene-modified cell infusion in a Kite-sponsored study. It helps researchers understand how treatments work over time and watch for any long-term effects.
Philadelphia, PennsylvaniaAges Any age - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Philadelphia, PennsylvaniaAges 12–85 - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Philadelphia, PennsylvaniaAges birth–38 years - NCT06208878Enrolling by invitation
Long-term follow-up for CRISPR CAR T therapy recipients
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Allentown, PennsylvaniaAges 18 years+
Hear when a new Hematologic Malignancy trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Hematologic Malignancy trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting hematologic malignancy studies listed above.
- University of Pennsylvania · 8 studies
- Children's Hospital of Philadelphia · 6 studies
- Fox Chase Cancer Center · 2 studies
- Lehigh Valley Topper Cancer Institute
- Nemours - Alfred I. duPont Hospital for Children
- St. Luke's University Health Network
- Thomas Jefferson University Hospital
What taking part in a hematologic malignancy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hematologic malignancy studies in Pennsylvania.
Common questions
- Are there hematologic malignancy clinical trials near Philadelphia?
- Yes. We're currently tracking 16 recruiting hematologic malignancy studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hematologic malignancy study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hematologic malignancy studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.